Literature DB >> 17925889

Current status of gene therapy for muscle diseases.

Christian Thirion1, Hanns Lochmüller.   

Abstract

The progress made in vector technology and preclinical evaluation of molecular and gene therapy for inherited muscle diseases led to initiation of the first clinical trials using plasmid and adeno-associated virus vectors, as well as antisense oligonucleotides. The scope of this review is to discuss the current status of gene therapy for muscular dystrophy and to highlight recent advances in viral, cell-based as well as molecular therapies. (c) 2007 Prous Science. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17925889     DOI: 10.1358/dnp.2007.20.6.1138159

Source DB:  PubMed          Journal:  Drug News Perspect        ISSN: 0214-0934


  2 in total

1.  New treatments for neuromuscular disease: optimism and obstacles.

Authors:  Hanns Lochmüller; Robert C Griggs
Journal:  Neurotherapeutics       Date:  2008-10       Impact factor: 7.620

Review 2.  Emerging genetic therapies to treat Duchenne muscular dystrophy.

Authors:  Stanley F Nelson; Rachelle H Crosbie; M Carrie Miceli; Melissa J Spencer
Journal:  Curr Opin Neurol       Date:  2009-10       Impact factor: 5.710

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.